Drug profile
Pimavanserin
GenericRadar assessment
Patent Radar Assessment
Grade A1
United States · 2030 Radar
Verification
HIGH
Why Grade A?
Acadia states its U.S. composition-of-matter patent covering pimavanserin and salts expires in 2030 after PTE; FDA identifies US7601740 with 2030-04-29 expiry.
Core Patent Expiry
2030-04-29
2030 Target Event
US7601740
Composition of Matter / Drug Substance · 2030-04-29
Core API Event?
Yes
Later Blocking Patents
Yes. NUPLAZID has later formulation/method patents extending into 2037-2039.
Generic Entry Assessment
Core composition-of-matter event in 2030. Later formulation/use patents and pediatric exclusivity/settlements must be evaluated for specific dosage forms.
Patent landscape
| Country | Patent no. | Type | Expiry | Status | Verified | Opportunity |
|---|---|---|---|---|---|---|
| United States | US7601740 | Composition of Matter / Drug Substance | 2030-04-29 | Protected | Yes | 48 |
API sourcing
Regulatory filing labels distinguish verified/listed records from records that have not yet been verified. “Not verified” does not mean that a filing does not exist.
| API | Manufacturer | Country | US DMF | KDMF | Japan MF | CEP | EU GMP | Status |
|---|---|---|---|---|---|---|---|---|
| Pimavanserin tartrate | Polpharma API | Poland | Not verified | Not verified | Not verified | Not verified | Not verified | Pipeline / DMF-ready |